AQUESTIVE THERAPEUTICS INC. - COMMON STOCK

Aquestive Therapeutics Names Sherry Korczynski as Chief Commercial Officer

22 Jul 2025 04:00:00 By Nasdaq GlobeNewswire

Aquestive Therapeutics Provides International Expansion Update for Anaphylm™ (epinephrine) Sublingual Film

15 Jul 2025 04:00:00 By Nasdaq GlobeNewswire

Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and Metabolism

07 Jul 2025 04:00:00 By Nasdaq GlobeNewswire

Aquestive Therapeutics to Present Positive Data from Pharmacokinetic and Pharmacodynamic Studies of Anaphylm™ (epinephrine) Sublingual Film at the CFAAR Food Allergy Summit

25 Jun 2025 04:00:00 By Nasdaq GlobeNewswire

Aquestive Therapeutics Announces FDA Acceptance of New Drug Application and PDUFA Date for Anaphylm™ for the Treatment of Severe Allergic Reactions

16 Jun 2025 04:00:00 By Nasdaq GlobeNewswire

Aquestive Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

12 May 2025 13:01:00 By Nasdaq GlobeNewswire

Aquestive Therapeutics to Participate in Citizens Life Sciences Conference

05 May 2025 04:00:00 By Nasdaq GlobeNewswire

Aquestive Therapeutics to Report First Quarter 2025 Financial Results and Recent Business Highlights on May 12 and Host Conference Call on May 13 at 8:00 a.m. ET

01 May 2025 04:00:00 By Nasdaq GlobeNewswire

Aquestive Therapeutics to Participate in Piper Sandler Spring Biopharma Symposium

09 Apr 2025 04:00:00 By Nasdaq GlobeNewswire

Aquestive Therapeutics Announces Positive Topline PK Results from its Pediatric Study and Completes the NDA Submission for Anaphylm™ (epinephrine) Sublingual Film

01 Apr 2025 04:00:00 By Nasdaq GlobeNewswire

Aquestive Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

05 Mar 2025 13:01:00 By Nasdaq GlobeNewswire

Aquestive Therapeutics to Participate in Two Upcoming Conferences in March

26 Feb 2025 04:00:00 By Nasdaq GlobeNewswire

Aquestive Therapeutics to Report Fourth Quarter 2024 Financial Results and Recent Business Highlights on March 5 and Host Conference Call on March 6 at 8:00 a.m. ET

20 Feb 2025 04:00:00 By Nasdaq GlobeNewswire

Aquestive Therapeutics to Present New Findings on Anaphylm™ (Epinephrine Sublingual Film) at the 2025 AAAAI Annual Meeting

12 Feb 2025 04:00:00 By Nasdaq GlobeNewswire

Aquestive Therapeutics to Participate in Oppenheimer 35th Annual Healthcare Conference

04 Feb 2025 04:00:00 By Nasdaq GlobeNewswire

Aquestive Therapeutics Provides Business Update and Outlines Key 2025 Objectives

13 Jan 2025 04:00:00 By Nasdaq GlobeNewswire

Aquestive Therapeutics Receives U.S. FDA Orphan Drug Exclusivity for Libervant® (diazepam) Buccal Film in Pediatric Patients with Seizure Clusters Ages Two to Five

19 Dec 2024 05:00:00 By Nasdaq GlobeNewswire

Aquestive Therapeutics Announces Positive FDA Feedback and Reaffirms NDA Submission Guidance for Anaphylm™ (epinephrine) Sublingual Film

02 Dec 2024 05:00:00 By Nasdaq GlobeNewswire

Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences

12 Nov 2024 05:00:01 By Nasdaq GlobeNewswire

Aquestive Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

04 Nov 2024 13:36:01 By Nasdaq GlobeNewswire